KYMERA THERAPEUTICS, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
KYMERA THERAPEUTICS, INC. (KYMR) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $68.34 million as of 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2024-02-22
- 2023-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $68.34M.
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $36.44M.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $0.00.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2023-12-31 | $68.34M 10-K · filed 2024-02-22 |
| 2022-12-31 | $36.44M 10-K · filed 2024-02-22 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |